Only a handful of people realize this.......
but VRAL seriously does have the most likely chance to become the next DNDN among all small cap biotechnology stocks.
Consider the following facts:
(1) VRAL scientific advisory team consists of the 2008 Nobel Prize Winner for Medicine (Dr. Luc Montgainer), a former U.S. Surgeon General (Dr. C Everett Koop), specialists at Harvard Medical School (Dr. Eric Rosenberg) and Marshall Phelps, Jr. (Microsoft’s lead IP/Patent attorney)
(2) The VGV-1 injectable drug has successfully completed Phase 1-3 trials in South Africa for the treatment of HIV/AIDS and has proven statistically verifiable results that confirm both the drugs safety and effectiveness in treating the HIV virus. Since Phases 1-3 have already been completed overseas, one could assume an FDA approval for the use of VGV-1 would be fast tracked.
(3) The CEO of VRAL (Haig Keledjian) is a very passionate scientist, not a businessman. He has been running VRAL since 1995 and is certainly not running a fly-by-night operation. He’s in it for the long term successful completion of FDA approvals for VGV-1.
(4) The mechanism of action for the VGV-1 injectable drug has been discovered by one of the most prominent Pharmacologists in the nation, Dr. Karen Newell from the University of Colorado.
(5) The injectable VGV-1 drug appears to have other autoimmune applications including the usage of the drug for treatment of Lyme’s Disease. VRAL has been awarded two separate grants for the R&D of VGV-1 usage to treat Lyme’s Disease. Since the mechanism of action involves the immune system and could potentially treat a variety of autoimmune diseases, VRAL is pursuing a separate patent for each unique VGV-1 treatment (i.e. one patent for HIV/AIDS treatment, one patent for Lyme’s Disease treatment, etc) which allows for a number of different revenue streams moving forward.
(6) Not only has the VGV-1 injectable drug proven its effectiveness in Phase 1-3 trials in South Africa, but it is substantially more cost effective than alternative HAART drugs. Whereas current HAART oral drugs must be taken for life, the VGV-1 injectable drug is administered through 16 intra-muscular injections over an eight week period.
(7) VRAL’s CEO Haig Keledjian personally told me that he believes their IND will be filed by the end of Q3 and that FDA Phase 1 trials will begin before the end of 2009.
(8) VRAL has successfully completed 5 clinical trials for the use of VGV-1 as an HIV/AIDS treatment and has proven statistically significant results.
VRAL is a sleeper for sure, but its only a matter of time before Haig Keledjian gets IND approval for VGV-1 and begins Phase I trials in the United State (Q4).
Once that happens we’re looking at a $0.25-$0.50 without a doubt and I think these may be conservative estimates given how hot the biotech sector has been lately.
